Bradley Herring
CIK 1813901 · EVP & CFO · last filed 2026-05-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
FOUR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
2202 N. IRVING STREET
ALLENTOWN, PA 16109
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OPLN | EVP & CFO | 16,190 | $34.90 | $565.0K | $0 | 2 | 2026-05-28 |
| OPENLANE, Inc. (KAR) Delisted | EVP & CFO | — | $30.88 | — | $0 | 1 | 2025-05-28 |
| Enfusion, Inc. (ENFN) Delisted | Chief Financial Officer | 216,357 | $10.76 | $2.33M | -$408.8K | 10 | 2025-04-21 |
| FOUR | CFO | 60,722 | $45.01 | $2.73M | -$732.0K | 10 | 2022-06-10 |
Recent Filings · Page 2 of 3
30 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-01-07 | Enfusion, Inc. (ENFN) Delisted | Notice (144) | −4,134 | -$41.9K | EDGAR |
| 2024-12-26 | Enfusion, Inc. (ENFN) Delisted | Sell (S) | −24,443 | -$259.3K | EDGAR |
| 2024-12-20 | Enfusion, Inc. (ENFN) Delisted | Notice (144) | −24,443 | -$259.4K | EDGAR |
| 2024-03-05 | Enfusion, Inc. (ENFN) Delisted | Mixed | +83,346 | $62.6K | EDGAR |
| 2024-01-10 | Enfusion, Inc. (ENFN) Delisted | Sell (S) | −4,088 | -$37.1K | EDGAR |
| 2024-01-09 | Enfusion, Inc. (ENFN) Delisted | Notice (144) | −2,090 | -$18.7K | EDGAR |
| 2024-01-09 | Enfusion, Inc. (ENFN) Delisted | Notice (144/A) | −1,998 | -$18.4K | EDGAR |
| 2024-01-08 | Enfusion, Inc. (ENFN) Delisted | Notice (144) | −1,998 | -$18.4K | EDGAR |
| 2023-01-09 | Enfusion, Inc. (ENFN) Delisted | Grant (A) | +40,688 | $0 | EDGAR |
| 2022-12-21 | Enfusion, Inc. (ENFN) Delisted | Grant (A) | +175,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.